APGE
USDApogee Therapeutics Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$55.000
Kõrge
$55.930
Madal
$52.340
Maht
1.04M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
3.7B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
0.66M
Börs
NGM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026,
Craig-Hallum Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $109
Craig-Hallum analyst Adam Vogel initiates coverage on Apogee Therapeutics with a Buy rating and announces Price Target of $109.
RBC Capital Maintains Outperform on Apogee Therapeutics, Raises Price Target to $70
RBC Capital analyst Brian Abrahams maintains Apogee Therapeutics with a Outperform and raises the price target from $60 to $70.
Apogee Therapeutics to Participate in Upcoming Conferences
SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), today announced that members of management will participate at the following investor conferences. Guggenheim 2nd
Mizuho Initiates Coverage On Apogee Therapeutics with Outperform Rating, Announces Price Target of $105
Mizuho analyst Joseph Catanzaro initiates coverage on Apogee Therapeutics with a Outperform rating and announces Price Target of $105.
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.